X4 Pharmaceuticals
BOSTON, MA · Biotechnology · 111 employees
X4 Pharmaceuticals is a fully integrated, commercial-stage biopharmaceutical company focused on driving progress for people living with rare immune disorders. The company listens to those whose challenges have been long overlooked, develops solutions to their most urgent health concerns, and delivers impact through its FDA-approved medication XOLREMDI® (mavorixafor), now commercially available in
Funding history
- Funding Round — $85.0M — Aug 2025
- Funding Round — $65.0M — Jun 2023
- Funding Round — $55.7M — Jul 2022
- Funding Round — $35.0M — Sep 2018
- Funding Round — $20.0M — Dec 2017
Recent signals
- Oct 23, 2025: SEC 8-K (1.01): On October 23, 2025, X4 Pharmaceuticals, Inc. entered into a material definitive agreement by signing an underwriting agreement with Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC as underwriters. The Company is issuing and selling 45,860,000 shares of its common stock at a public offering price of $2.90 per share. Additionally, it is providing pre-funded warrants to purchase 700,000 shares at a price of $2.899 per share, factoring in a nominal exercise price of $0.001 per share. The underwriters have a 30-day option to purchase additional shares, indicating a strategic move to raise substantial capital through this offering.
- Aug 25, 2025: Raised $85.0M
- Feb 19, 2025: Launched X4 Pharmaceuticals Announces Exclusive Distribution Agreement for XOLREMDI® in WHIM Syndrome with taiba rare.
- Jun 01, 2023: Raised $65.0M
- Jul 19, 2022: Raised $55.7M
- Sep 21, 2018: Raised $35.0M
- Dec 04, 2017: Raised $20.0M
- Nov 15, 2017: Raised $25.8M
See plans & pricing → Track X4 Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.